中文Vientiane, Laos - October 12 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Binimetinib and Encorafenib have been approved by the Ministry of Health of Laos.
Approved drugs are:
Binimetinib is an ATP non-competitive, reversible inhibitor that inhibits the kinase activity of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. MEK protein is an upstream regulator of the extracellular signal-related kinase (ERK) pathway, which promotes cell proliferation. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF that activate MEK. Binimetinib inhibits the activation of MEK by BRAF and inhibits MEK kinase activity. Approved in Laos under the trade name MEKTODX, Laos registration number: 09L1096/24
Encorafenib is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers, including melanoma and colorectal cancer. Trade name approved in Laos: BRATODX, Lao registration number: 09L1201/24
Encorafenib is used in combination with binimetinib to treat patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.
About BigBear Pharmaceuticals:
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Forward-Looking Statements:
Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.